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Background: Autonomic dysfunction is common in patients with Parkinson’s disease (PD). We report autonomic
function test results in a prevalent, largely untreated, Tanzanian population of PD patients, at different disease
stages and investigate the relationship between autonomic dysfunction and mortality.
Methods: Ewing’s battery of autonomic tests was carried out on a prevalent population of PD patients living in
the rural Hai district of Tanzania. Where possible, all four tests were performed in the patient’s home. The main
outcome of interest was the presence of abnormalities of sympathetic or parasympathetic function. Information
on medications used and other co-morbidities was recorded.
Results: Autonomic function tests were recorded for 29 subjects, of whom 3 were on medication at the time of
assessment. Of the 26 unmedicated patients, 14 (53.8%) had at least one abnormal test result for autonomic
function, of whom only 3 (21.4%) were in late stage disease (Hoehn and Yahr stage IV or V), compared to 7
(58.3%) of 12 with normal autonomic function tests in late stage disease. Ten subjects had died at 5-year follow-up,
but there was no association between mortality and autonomic function test abnormalities.
Conclusions: In unmedicated subjects, many patients in late stage disease had relatively preserved autonomic
function, compared to those in early stage disease. In people with PD who are taking medication, it may be that
when autonomic dysfunction presents in late stage disease it is often due to side effects of medication rather
than the disease itself.
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Autonomic symptoms are frequently seen in patients with
Parkinson’s disease (PD). These include urinary symptoms,
sweating disturbance, constipation, sexual dysfunction and
blurred vision [1]. Dysregulation of parasympathetic car-
diovascular control mechanisms is a frequent compli-
cation of early stage PD [2,3]. Such dysregulation can
manifest itself as a range of measurable changes in cardiac
function such as heart rate variability and orthostatic
hypotension (OH). OH is thought to be present in around* Correspondence: ariseric4@gmail.com
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reproduction in any medium, provided the or50% of people with PD and can be particularly dis-
tressing, with an increased likelihood of serious injury
from falls [2,4].
It is thought that these autonomic symptoms may be
linked to PD medication as well as neurodegenerative
disease related changes in the function of the autonomic
nervous system [5]. Therefore, data from unmedicated
populations are of particular interest. The primary aim
of this study was to investigate autonomic dysfunction
within a prevalent, largely untreated, PD population
from rural Tanzania [6]. Secondary aims were to consider
associations with demographic and clinical data and
five-year mortality.. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Ethical approval for the study was obtained through the
National Institute of Medical Research, Tanzania and the
Newcastle and North Tyneside Ethics Committee in the
UK. Patient information sheets and consent forms were
translated into Swahili by a Tanzanian PD nurse specialist.
All patients were identified from a previously reported
prevalence study [6]. After obtaining informed consent,
all patients were assessed either in their own homes or,
if possible, a local health clinic by a research doctor
(C.D.). Translation was through local assistant medical
officers, census enumerators and a PD nurse specialist. PD
was diagnosed according to the UK Brain Bank criteria
[7]. The patients were videoed and reviewed by a move-
ment disorders specialist (R.W.) to confirm the diagnosis.
Autonomic function tests
The autonomic function tests were based on Ewing’s
battery of four tests [8]. The tests were all carried out by
the research doctor who had been trained in PD and
autonomic function testing.
Supine and standing BP: sympathetic function
Baseline systolic and diastolic BP was measured in a
supine position after five minutes resting quietly. Three
measurements were taken at one-minute intervals and
the mean calculated. The patient was then asked to
stand up. Three standing BP results were recorded;
immediately on standing, after 30 seconds and after one
minute standing up. The lowest systolic BP value of the
three was recorded. A decrease in systolic BP, from the
mean supine BP, of greater than 20 mmHg was recorded
as an abnormal result.
BP response to hand grip: sympathetic function
BP response to hand grip was measured with a hand-
held sphygmomanometer. Patients were given the in-
struction “to squeeze the machine as tightly as possible”
with their dominant hand to determine their maximum
possible power, and then to hold it at one third of their
maximum total power for as long as possible up to five
minutes. During this period, BP was measured three
times at one minute intervals and the highest result
noted. The mean resting diastolic BP was subtracted
from the highest diastolic BP during handgrip and the
result recorded. Failure to increase diastolic BP by more
than 20 mmHg during the prolonged handgrip was
recorded as abnormal.
Heart rate response to standing: Parasympathetic
function
To record heart rate response to standing, patients were
asked to lie down quietly for at least 5 minutes. The
patient had the 12 lead ECG machine attached withcontinuous rhythm strip recording. When the patient
stood up a point was marked on the ECG trace and
recording continued for a further 30 beats. R-R variabil-
ity was measured as the ratio of the longest R-R interval
(at or around 30 beats) compared to the shortest R-R
interval (at or around 15 beats). This ratio (30:15 ratio)
was then classified as being abnormal if ≤ 1.00.
Heart rate variability to deep breathing: parasympathetic
function
Respiratory heart rate variability was measured with a 12
lead ECG machine put on continuous rhythm strip
recording, with the patient lying supine and relaxed
breathing in and out slowly at a rate of six breaths per
minute for one minute.
Other data collected
Demographic data (age and gender) were also
collected. The Unified Parkinson’s Disease Rating
Scale (UPDRS) [9] and the 39-item Parkinson’s Disease
Questionnaire (PDQ-39), measuring quality of life, were
administered [10].
Five-year follow-up
All patients were followed-up at five years after initial
assessment. Details of any patient who had died during
this period were recorded.
Statistical analysis
The data were quantitative in nature and collected at a
nominal, ordinal and interval/ratio level. They were
analyzed using standard statistical software, PASW-18
for windows (PASW, Chicago, IL, USA). Two-tailed tests
were used throughout, the significance level was set at
α = 0.05.
Results
Thirty-two cases (22 males, 68.8%) of PD were identified
by the prevalence study [6]. The mean age was 73.8 years
(standard deviation 12.90). For three cases (2 males),
none of the four tests of autonomic function could be
completed successfully and they are excluded from the
current study. A further three cases were on medication
at the time of assessment; data for these cases are ana-
lysed separately. Two subjects were taking benzhexol
and one was taking sinemet. Only two other cases had
received any type of anti-parkinsonian medication in
the past though both had not taken medication for
some time.
For the test of heart rate variability to deep breathing,
many of the patients, not just those with cognitive
impairment, found it difficult to understand the instruc-
tions for breathing slowly without trying to breathe as
deeply as they could or hold their breath. It took several
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target of 6 breaths per minute was not always achieved.
It was felt these data were unreliable and they were not
utilised.
Untreated subjects (n = 26)
Results of autonomic function tests are shown in Table 1.
For the test of heart rate response to standing, 9 patients
were unable or unwilling to stand whilst connected to
the ECG machine for long enough for a recording to be
made. For the test of BP response to standing, some
patients were unable to stand for long enough for 3
complete BP recordings to be completed. In these cases,
if the first recording was normal then this result was
accepted and no further recording made, thus data for
all 26 patients are presented. For the tests of BP
response to hand grip, 4 patients were unable to grip for
long enough to make a satisfactory recording.
Of the 26 untreated patients who had at least one
autonomic test performed, 14 (53.8%) had one or more
abnormal test result. Interestingly, only 3 (21.4%) of
those with abnormal results were in late stage disease
(Hoehn and Yahr stage IV or V), compared to 7 (58.3%)
of the 12 with normal test results. This difference was
not significant (χ2(1) = 3.718, p = 0.054), although this
is likely to be in part due to the small numbers in-
volved, representing a type II error. However, having
at least one abnormal autonomic function test result
was associated with greater quality of life by PDQ-39
(U = 21.5, z = −3.216, p = 0.001), greater physical func-
tion (U = 38.0, z = −2.377, p = 0.017) and improved
UPDRS score (U = 31.5, z = −2.493, p = 0.013). All three of
these variables are also markers for disease severity.
At 5-year follow up, 10 (38.5%) of the 26 untreated
subjects had died. There was no association between
having at least one abnormal autonomic function test
and age, sex or 5-year mortality.Table 1 Results of autonomic function tests and outcomes fo
Untreated patients (n = 26)
Heart rate response to standing
BP response to hand grip
BP response to standing
One or more abnormal tests
Died by 5-year follow-up
Treated patients (n = 3)
Heart rate response to standing
BP response to hand grip
BP response to standing
One or more abnormal tests
Died by 5-year follow-up
BP = blood pressure.Treated subjects (n = 3)
Of the three treated subjects, one had abnormal heart
rate response to standing, two had abnormal BP re-
sponse to hand grip and one had abnormal BP response
to standing (see Table 1). Two of the three subjects had
at least one abnormal test of autonomic function and
two were in late stage disease based on Hoehn and Yahr
score, both of whom had died at 5-year follow-up.
Discussion
Rates of autonomic dysfunction
Autonomic function test abnormalities were frequently
seen in this group of patients. The most common abnor-
mality seen was heart rate variability to hand grip, which
was present in over half of those tested. Interestingly,
the least common abnormality was OH which would be
the baseline test performed in most medical clinics. Our
estimates of the prevalence of autonomic dysfunction
are similar to those reported in other populations in
high-income countries [11]. Higher rates have been
reported in another study, with 16 of 20 patients of stage
I or II disease displaying signs of autonomic dysfunction,
with cardiac symptoms particularly common [3]. In a
Nigerian study, Okubadejo et al [12] reported just over
half of patients with PD aged 65 years or over had para-
sympathetic dysfunction.
Association between autonomic dysfunction and disease
severity
The presence of autonomic dysfunction was associated
with less advanced disease, less disability and greater
quality of life. Although the reasons for this are far from
clear, it appears that, in our cohort autonomic dysfunc-
tion is more common in early stage disease. Indeed, it is
remarkable that in untreated patients, over two-thirds at
Hoehn and Yahr stage IV or V had no autonomic
dysfunction. It has previously been suggested thatr treated and untreated patients
4 (23.5%) abnormal, 13 (76.5%) normal, 9 assessment not completed
11 (50%) abnormal, 11 (50%) normal, 4 assessment not completed
1 (3.8%) abnormal, 25 (96.2%) normal
14 (53.8%)
10 (38.5%)
1 (33.3%) abnormal, 2 (66.7%) normal
2 (66.7%) abnormal, 1 (33.3%) normal
1 (33.3%) abnormal, 2 (66.7%) normal
2 (66.7%)
2 (66.7%)
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disease are a worrying or atypical feature, favouring
multiple system atrophy as the underlying diagnosis [5].
There is evidence that autonomic involvement can occur
in the early stages of PD; in one study, 38% of patients
with abnormal autonomic function tests were in the first
5 years of their disease [11].
Previous research has suggested no significant associ-
ation between autonomic dysfunction and mortality in
people with PD [13]. In our largely untreated population,
the lack of dysfunction in late stage disease may partly
explain this observation.
Appropriateness of the tests performed and limitations
Our figures for autonomic dysfunction are likely to
be an under-estimate. Only two of the four tests
could be performed satisfactorily on three-quarters of
the cohort. If more patients had been able to undergo
testing it is likely that our estimate would have been
higher. Difficulties in performing autonomic tests
have been reported in other centres too, even when
conducting tests in a hospital setting. Magerkurth et
al [11] documented that 20% of their patients could
not satisfactorily perform the Valsalva manoeuvre with
cardiovascular monitoring.
The test of R-R variability could not be performed on
some patients due to frailty, a problem that could have
arisen in any community-based PD cohort and was not
unique to SSA. The fourth test, R-R variation with deep
breathing would have been possible to test, but patients
did not fully understand the instructions and in many
cases the patient was breathing more quickly than the
test required. In the study by Magerkurth et al [11] only
1 patient out of 141 tested had any abnormality in heart
rate variability on deep breathing even though 56%
reported one or more autonomic symptoms, so this may
not be the most sensitive test for detecting autonomic
dysfunction in PD. The autonomic tests reported meas-
ure cardiovascular reflexes and we did not test bladder
function or sweating. In this setting, asking personal
questions about continence was often difficult and ques-
tions on sexual function were not discussed, so we have
no data on the frequency of erectile dysfunction in men.
As the patients were visited at home, often many of the
family, neighbours and local children had come to see
what was going on. It was too dark inside the mud huts
to conduct the interview indoors, so interviews were
conducted in the communal courtyard, and it was not
appropriate to ask intimate questions in that location.
Finally, we acknowledge that the small number of
patients involved in our study, limits the extent to which
conclusions can be drawn regarding their significance.
However, in this resource limited setting, where diagno-
sis is rare, recruiting large numbers of PD patients isdifficult. This is reflected in the extremely limited amount
of previous data regarding PD in SSA.
Conclusions
No previously published study has investigated a pre-
dominantly unmedicated population with such a wide
variation of disease stage. Autonomic function test
abnormalities were surprisingly uncommon in late stage
disease. This may suggest that when such abnormalities
are seen in late stage disease, there may be a significant
contribution from anti-parkinsonian medication.
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